IMCR - Immunocore's Pipeline Is Among The Strongest In Broader Biotech Universe: Analyst | Benzinga

H.C. Wainwright analyst Patrick R. Trucchio reiterated a Buy rating on Immunocore Holdings Plc (NASDAQ: IMCR) with a price target of $90.

On January 5, Immunocore announced multiple near-term data readouts are expected and expanded the pipeline to autoimmune disease indications, both clear positives for shareholders, per the analyst.

Immunocore has a proven platform with one approved drug, KIMMTRAK (tebentafusp-tebn), a T cell receptor (TCR) bispecific immunotherapy, and a broad pipeline across discovery, Full story available on Benzinga.com